Covaxin, which is currently in Phase I/II human trials. The results show reduction in replication of the virus in the nasal cavity, throat and lung tissues of monkeys."These results demonstrate the protective efficacy in a live viral challenge model," said Bharat Biotech.Bharat Biotech proudly announces the animal study results of COVAXIN™ - These results demonstrate the protective efficacy in a live viral challenge model.Read more about the results here - https://t.co/f81JUSfWpD@icmr_niv #BharatBiotech #COVAXIN #Safety #Vaccine #SARSCoV2 pic.twitter.com/fva1SOcLOrCovaxin, being developed by the Indian Council of Medical Research and Bharat Biotech, is being tested at 12 institutes across India.A tw-dose vaccination regimen of inactivated.